1. Home
  2. HLI vs UTHR Comparison

HLI vs UTHR Comparison

Compare HLI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Houlihan Lokey Inc.

HLI

Houlihan Lokey Inc.

HOLD

Current Price

$179.65

Market Cap

14.4B

Sector

Finance

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLI
UTHR
Founded
1972
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
20.3B
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
HLI
UTHR
Price
$179.65
$488.92
Analyst Decision
Hold
Buy
Analyst Count
9
12
Target Price
$205.38
$495.08
AVG Volume (30 Days)
367.8K
424.3K
Earning Date
10-30-2025
10-29-2025
Dividend Yield
1.34%
N/A
EPS Growth
26.59
16.08
EPS
6.19
26.38
Revenue
$2,565,361,000.00
$3,128,400,000.00
Revenue This Year
$15.23
$13.64
Revenue Next Year
$13.29
$5.78
P/E Ratio
$29.04
$18.55
Revenue Growth
21.00
13.50
52 Week Low
$137.99
$266.98
52 Week High
$211.78
$492.62

Technical Indicators

Market Signals
Indicator
HLI
UTHR
Relative Strength Index (RSI) 49.37 68.10
Support Level $171.77 $470.13
Resistance Level $178.75 $492.62
Average True Range (ATR) 3.98 10.72
MACD 1.22 -0.53
Stochastic Oscillator 81.63 89.55

Price Performance

Historical Comparison
HLI
UTHR

About HLI Houlihan Lokey Inc.

Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: